CoChat

Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade

Open access

Published version of a preprint

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n = 978) and on-treatment (n = 171) ctDNA samples across 16 advanced-stage tumor types from three phase I/II trials of durvalumab (± the anti-CTLA4 therapy tremelimumab). Higher pretreatment variant allele frequencies (VAF) were associated with poorer overall survival (OS) and other known prognostic factors, but not objective response, suggesting a prognostic role for patient outcomes. On-treatment reductions in VAF and lower on-treatment VAF were independently associated with longer progression-free survival and OS and increased objective response rate, but not prognostic variables, suggesting that on-treatment ctDNA dynamics are predictive of benefit from immune checkpoint blockade. Accordingly, we propose a concept of “molecular response” using ctDNA, incorporating both pretreatment and on-treatment VAF, that predicted long-term survival similarly to initial radiologic response while also permitting early differentiation of responders among patients with initially radiologically stable disease. Significance: In a pan-cancer analysis of immune checkpoint blockade, pretreatment ctDNA levels appeared prognostic and on-treatment dynamics predictive. A “molecular response” metric identified long-term responders and adjudicated benefit among patients with initially radiologically stable disease. Changes in ctDNA may be more dynamic than radiographic changes and could complement existing trial endpoints. This article is highlighted in the In This Issue feature, p. 1775

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-0047

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

Items 201–300 of 376

Metadata

Authors
Zhang, Q., Luo, J., Wu, S., Si, H., Gao, C., Xu, W., Abdullah, S. E., Higgs, B. W., Dennis, P. A., van der Heijden, M. S., Segal, N. H., Chaft, J. E., Hembrough, T., Barrett, J. C., & Hellmann, M. D.
Affiliations
  • 1Translational Medicine, Early Oncology, AstraZeneca, Gaithersburg, Maryland.
  • Memorial Sloan Kettering Cancer Center (US)
  • 3Early Oncology Statistics, AstraZeneca, Gaithersburg, Maryland.
  • AstraZeneca (United States) (US)
  • 5Division of Molecular Carcinogenesis and Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.
Corresponding author
Hellmann, Matthew D.
Venue
Cancer Discovery
Published
2020-12-01
Volume
10
Issue
12
Pages
1842-1853
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3049083268
Cited by
348
References
53
Citations by year
2026: 31 · 2025: 72 · 2024: 60 · 2023: 70 · 2022: 54 · 2021: 54 · 2020: 6
FWCI
16.61
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • AstraZeneca (NCT01693562, NCT02087423, NCT02261220)
  • Memorial Sloan Kettering Cancer Center (P30 CA008748)
  • Damon Runyon Cancer Research Foundation (CI-98-18)
  • Parker Institute for Cancer Immunotherapy
  • NIH (T32-CA009207, K30-UL1TR00457)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
circulating tumor DNA, immune checkpoint blockade, durvalumab, tremelimumab, variant allele frequency, molecular response, prognostic factors, predictive biomarkers, overall survival, progression-free survival, objective response rate, pan-cancer analysis, CTLA-4 blockade
MeSH terms
Circulating Tumor DNA, Immune Checkpoint Inhibitors, Humans, Neoplasms, Prognosis, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.